A new boosted STA®-ImmunoDef intrinsic factor line

Back to list

As part of Stago's continuous improvement commitment, STA®-ImmunoDef* intrinsic factor kits were developed as a new generation of Deficient Plasmas with enhanced performances.
A new boosted STA®-ImmunoDef intrinsic factor line

Intrinsic factor measurement allows for the characterisation of clinically significant conditions such as Haemophilia A (Factor VIII) and B (Factor IX). Robust and reliable reagents promote increased laboratory efficiency.

* Availability depending upon the country

Optimum analytical performance for even more reliable patient results

  • Extended working range with one calibration curve:

- STA®-ImmunoDef VIII : 0,7-400%
- STA®-ImmunoDef IX : 0,7-300%
- STA®-ImmunoDef XI : 1-200%
- STA®-ImmunoDef XII : 3-300%
- No more low calibration curve needed

  • Perfect correlation of low patient results

 

  • Very good precision on the entire working range

Adapted reagents whatever the clinical context, especially for the diagnosis and monitoring of haemophilia

  • Enhanced reagents on board stability (8 h)
  • - Assay available for a long time
  • Stability and robustness of calibrations
  • - No systematic calibration needed

Efficient reagents for an easier laboratory practice

Compliant with current international guidelines

  • Calibrators & controls assayed against WHO International Standards*
  • - For standardised results
  • Residual activity of immunodepleted factor <1%*
  • - Ensures reliability of patient's for low results
  • Other coagulation factors at normal levels
  • - For specific measurements
  • Addition of VWF (STA®-ImmunoDef VIII)
  • - Adapted to Bethesda and Nijmegen inhibitor assays

*STA®-ImmunoDef VIII, STA®-ImmunoDef IX, STA®-ImmunoDef XI

Florence C., Haemostasis Project Manager (R&D), Gennevilliers – France

"I joined Stago in 2002 when I finished my engineering course. First in the Quality Control department, and then six months later in R&D, I was able to learn more about the company and the diversity of careers in it. When Stago offered me a job in the Haemostasis department in Reagent R&D, my first work was on research projects. The regular sharing of experience that I enjoyed was of great benefit. Since 2006, I’ve moved on to development projects which have helped me build up my project management skills. In parallel, with the expansion of Stago, I’ve been able to build up a team and find out about management. The different projects I get given, the opportunity that Stago gives me to take part in international conferences, and a great many courses mean I carry on learning every day."